Given the known immunosuppressive effects of PKC and PI3K inhibition, we hypothesized that treatment with sotrastaurin and alpelisib may result in immunosuppressive effects, which may impact anti-tumor activity. The gene discussed is PRRT2; the disease is neoplasm.